Back to results
US 2019/0169197 A1Published application
Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treatment of inflammation
AssigneeChemoCentryx, Inc.
InventorsAntoni Krasinski, Sreenivas Punna, Solomon Ungashe, Qiang Wang, Yibin Zeng
Life of this patent
Estimating the term…
Abstract
Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases and as controls in assays for the identification of CCR2 antagonists.
Claims20
A compound of the formula (I) or a salt thereof:
- wherein
- R1 and R2 are each independently hydrogen, halogen, C1-8 alkyl, —CN, or C1-8 haloalkyl, provided that at least one of R1 or R2 is other than hydrogen;
- each R3 is independently hydrogen, halogen, or C1-4 alkyl;
- R4 is hydrogen or C1-8 alkyl;
- R5 is hydrogen, halogen, or C1-8 alkyl optionally substituted with methoxy;
- R6 is hydrogen or C1-4 alkyl;
- R11 is selected from the group consisting of hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5-to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocycle;
- X1 is CR7, N, or NO;
- X2 and X4 are each independently N or NO;
- X3 is CR7;
- X6 and X7 are each independently selected from CR7, N, and NO;
- each R7 is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, —CN, —NO2, —OR8, —OC(O)R8, —CO2R8, —C(O)R8, —C(O)NR9R8, —OC(O)NR9R8, —NR10C(O)R8, —NR10C(O)NR9R8, —NR9R8, —NR10CO2R8, —SR8, —S(O)R8, —S(O)2R8, —S(O)2NR9R8, —NR10S(O)2R8, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl and substituted or unsubstituted 3- to 10-membered heterocyclyl;
- each occurrence of R8, R9, and R10 is independently selected from the group consisting of hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, aryl, or heteroaryl;
- or R8 and R9 or R8 and R10, together with the atom(s) to which they are attached, form an substituted or unsubstituted 5-, 6-, or 7-membered ring.
11 more elements
A compound of the formula (II) or a salt thereof:
- wherein
- R1 and R2 are each independently hydrogen, halogen, substituted or unsubstituted C1-8 alkyl, —CN, or C1-8 haloalkyl, provided that at least one of R1 or R2 is other than hydrogen;
- R4 is hydrogen;
- R5 is halogen or C1-8 alkyl;
- R11 is selected from the group consisting of hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5-to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocycle.
2 more elements
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.